JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Lantheus Holdings Inc

Cerrado

SectorSalud

55.43 -0.63

Resumen

Variación precio

24h

Actual

Mínimo

55.03

Máximo

56.86

Métricas clave

By Trading Economics

Ingresos

5.8M

79M

Ventas

5.3M

378M

P/B

Media del Sector

15.46

37.003

Margen de beneficio

20.832

Empleados

808

EBITDA

7.7M

123M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+41.37% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-992M

4B

Apertura anterior

56.06

Cierre anterior

55.43

Noticias sobre sentimiento de mercado

By Acuity

68%

32%

338 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Lantheus Holdings Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

30 oct 2025, 23:32 UTC

Acciones populares

Stocks to Watch: Amazon, Reddit, SPS Commerce

30 oct 2025, 23:02 UTC

Ganancias

AIA Group 3Q Value of New Business Grew

30 oct 2025, 23:45 UTC

Charlas de Mercado

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30 oct 2025, 23:00 UTC

Ganancias

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30 oct 2025, 22:59 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

30 oct 2025, 22:59 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30 oct 2025, 22:56 UTC

Charlas de Mercado

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30 oct 2025, 22:35 UTC

Ganancias

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30 oct 2025, 22:35 UTC

Ganancias

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30 oct 2025, 22:31 UTC

Ganancias

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30 oct 2025, 22:29 UTC

Ganancias

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30 oct 2025, 22:27 UTC

Ganancias

Minas Buenaventura 3Q EPS 66c >BVN

30 oct 2025, 22:27 UTC

Ganancias

Minas Buenaventura 3Q Rev $431M >BVN

30 oct 2025, 22:27 UTC

Ganancias

Minas Buenaventura 3Q Net $179M >BVN

30 oct 2025, 22:16 UTC

Charlas de Mercado
Ganancias

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30 oct 2025, 22:14 UTC

Ganancias

Review & Preview: A Tech Earnings Storm -- Barrons.com

30 oct 2025, 22:00 UTC

Ganancias
Adquisiciones, fusiones, absorciones

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30 oct 2025, 21:39 UTC

Ganancias

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 oct 2025, 21:26 UTC

Ganancias

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 oct 2025, 21:14 UTC

Charlas de Mercado
Ganancias

Apple Sees Record Quarterly Services Revenue -- Market Talk

30 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

30 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30 oct 2025, 21:04 UTC

Ganancias

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30 oct 2025, 21:03 UTC

Ganancias

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30 oct 2025, 21:03 UTC

Ganancias

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30 oct 2025, 21:00 UTC

Ganancias

Eldorado Gold Skouries on Track for 1Q of 2026

30 oct 2025, 21:00 UTC

Ganancias

Eldorado Gold 3Q Adj EPS 41c >EGO

30 oct 2025, 21:00 UTC

Ganancias

Eldorado Gold 3Q Rev $434.7M >EGO

30 oct 2025, 21:00 UTC

Ganancias

Eldorado Gold 3Q Net $56M >EGO

30 oct 2025, 21:00 UTC

Ganancias

Eldorado Gold 3Q EPS 27c >EGO

Comparación entre iguales

Cambio de precio

Lantheus Holdings Inc Esperado

Precio Objetivo

By TipRanks

41.37% repunte

Estimación a 12 meses

Media 79 USD  41.37%

Máximo 99 USD

Mínimo 70 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lantheus Holdings Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

9 ratings

6

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

79.24 / 103.64Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

338 / 373 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
help-icon Live chat